PsiThera
PrivateLast Round
Series A
Dec 10, 2025
Total Funding Raised
$95M
Company Overview
PsiThera is a biotechnology company that develops oral medicines for immunology and inflammation by using its computational intelligence platform, QUAISAR.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Medical AI
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PsiThera Comps
Public and private peers based on sector, stage, and business model.
PsiThera Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Dec 10, 2025 | ||||
| Series A | Dec 10, 2025 |
PsiThera Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Lightstone Ventures | Series A |
| Eurofarma Ventures | Series A |
| Samsara BioCapital | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Dec 17, 2025
Eric Shaff, formerly of Seres Therapeutics, named new CEO.
- Dec 10, 2025
$48M round completed.
PsiThera Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about PsiThera's valuation, stock price, and market status.
